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hematopoietic stem cells trigger diabetic
neuropathy in mice by cell fusion
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Diabetic neuropathy is an incurable disease. We previously identified a mechanism by which
aberrant bone marrow-derived cells (BMDCs) pathologically expressing proinsulin/TNF-α
fuse with residential neurons to impair neuronal function. Here, we show that CD106-positive
cells represent a significant fraction of short-term hematopoietic stem cells (ST-HSCs) that
contribute to the development of diabetic neuropathy in mice. The important role for these
cells is supported by the fact that transplantation of either whole HSCs or CD106-positive ST-
HSCs from diabetic mice to non-diabetic mice produces diabetic neuronal dysfunction in the
recipient mice via cell fusion. Furthermore, we show that transient episodic hyperglycemia
produced by glucose injections leads to abnormal fusion of pathological ST-HSCs with
residential neurons, reproducing neuropathy in nondiabetic mice. In conclusion, we have
identified hyperglycemia-induced aberrant CD106-positive ST-HSCs underlie the develop-
ment of diabetic neuropathy. Aberrant CD106-positive ST-HSCs constitute a novel ther-
apeutic target for the treatment of diabetic neuropathy.
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Cell-to-cell fusion (cell fusion) is a physiological processwhich can be observed during organogenesis in utero, aswell as after birth1. An example would be the process of
fertilization, in which a sperm fuses with an egg2,3. Postnatally,
different types of somatic cells have also been found to fuse with
other cells during various physiological processes. Skeletal muscle
cells4,5, osteoclasts6, syncytiotrophoblasts7, and Langhans giant
cells8 often appear as multinucleated cells, which are thought to
be a product of homotypic cell fusion. Bone marrow-derived cells
(BMDCs) can also be a fusion partner to other types of cells,
including Purkinje neurons, cardiomyocytes, or hepatocytes9,10,
leading to the formation of heterotypic multinucleated cells.
Cell fusion is often involved in various pathological processes.
For example, heterotypic cell fusion has been found to be asso-
ciated with the development of metastatic cancers11,12. In addi-
tion, we previously reported that abnormal heterotypic cell fusion
occurs between BMDCs and both hepatocytes and neurons, with
the latter contributing to the development of diabetic neuropathy
(DN)13,14.
DN, a major complication of diabetes mellitus (DM), is
induced at a relatively early stage after the development of dia-
betes, and progressively worsens throughout life. Patients afflicted
with DN often develop gangrene in their lower extremities during
the chronic stage, and experience major deterioration in quality of
life15. A number of pathological mechanisms for the development
of DN have been proposed, including ischemia, up-regulation of
inflammatory cytokines such as tumor necrosis factor (TNF)-α
and interleukin-6 (IL-6), and deficiency of nerve growth factor
(NGF), all of which are thought to be involved in the develop-
ment of DN. To date, therapeutic approaches targeting these
pathways have yielded little success. Novel hypotheses need to be
tested to enable the formulation of new treatments for DN16.
In the last dozen years, our group has found that cell fusion
between BMDCs and nerve fibers or neurons in the dorsal root
ganglion (DRG) may underlie the development of DN in type 1
and type 2 diabetic mouse models13,17,18. However, the specific
cell type of BMDCs responsible for DN remains elusive. In this
study, we categorized bone marrow cells in diabetic mice into
specific subtypes and attempted to identify a specific cell type for
the development of neuropathy in various diabetic mouse models.
We found that CD106-positive cells, a class of hematopoietic
stem cell in Lineage (-), c-kit (+) and Sca-1 (+) (LSK) cells, are
the culprits that underlie the pathogenesis of DN, and thus
constitute a novel therapeutic target for the treatment of this
highly prevalent diabetic complication.
Results
Fusion of BMDCs with neurons associated with neuronal
dysfunction. Diabetic neuropathy (DN) is characterized by a
sensory disorder featuring delayed sensory nerve conduction
velocity (SNCV)19. In both type 1 and type 2 DM, the mechanism
underlying the delay of SNCV has been found to be associated
with progressive segmental demyelination and/or axonal
degeneration20; however, the role of hyperglycemia in the
development of nerve dysfunction remains unknown.
We previously reported that abnormal BMDCs are a cause of
neuronal injury in diabetes, based on our data that BMDCs
exposed to diabetic conditions migrate to the DRG and fuse with
DRG neurons13. Interestingly, the BMDCs in mice with diabetic
neuropathy were found to express proinsulin21 and TNF-α13, and
caused chronic inflammation at the fusion site, leading to
neuronal dysfunction22–25. However, the overlap phenomenon
could also be accounted for by an alternative possibility that
BMDCs could have directly differentiated into neurons in the
absence of cell fusion.
In order to address this issue, we created a mouse model in
which a marker (red fluorescence) would be created only by the
cell fusion process. We therefore transplanted total bone marrow
(TBM) from Ayu-1 Cre transgenic mice into LoxP-stop-LoxP-
tdTomato mice, which were transgenic mice with the tdTomato
gene inserted downstream of the STOP sequence in the LoxP site
(Ayu-1 TBM BMT to lsl-tomato) (Fig. 1a). If cell fusion had
occurred in this mouse model, the Cre-recombinase driven by the
Ayu-1 promoter26 would react with LoxP, removing the floxed
stop sequence, enabling the expression of tdTomato. After
inducing diabetes in these mice using STZ (confirmed by
hyperglycemia and delayed SNCV 12 weeks later, Fig. 1b, c),
we examined deletion of the stop sequence by PCR. As shown in
Fig. 1d, a 545 bp PCR product was detected in DRG neurons of
nonDM mice, but not in those of STZ-DM mice, suggesting that
the stop sequence in the nuclei of DRG neurons had been deleted
by the Cre-recombinase of BMDCs as a consequence of cell
fusion between these cells. Consistent with this scenario,
histological analyses also revealed the occurrence of tdTomato
fluorescence (red) in the DRG neurons of STZ-DM recipients but
not in nonDM recipients (Fig. 1e), indicating cell–cell fusion
between the donor and recipient cells (Fig. 1e, f).
Previously, we demonstrated that BMDCs expressing proinsu-
lin/TNF-α were also positive for CD4513. This time, we confirmed
that this type of cell was detected in both type of DM mice, but
not in nonDM mice, and in particular in the hematopoietic stem
cell fraction (Lineage (-), c-kit (+) and Sca-1 (+): LSK)
(Supplementary Fig. 1)18. These results suggested that the
presence of type 1 and type 2 DM is associated with the
appearance of an abnormal cell fraction among the hematopoietic
stem cells in the bone marrow.
Diabetic bone marrow cells can cause neuropathy in non-
diabetic mice. We reasoned that functionally-impaired BMDCs
in neural tissues are likely derived from abnormal hematopoietic
stem cells in the bone marrow, which would be a key factor for
the incurableness of DN only by glycemic control. In order to
further investigate the pathological characters of BMDCs, we next
isolated TBM cells from STZ-DM mice, transplanted them into
wild type mice, and investigated whether diabetic BMDCs would
lead to cell fusion and induce neuropathy even in normoglycemic
mice (Supplementary Fig. 2).
First, we compared nonDM mice transplanted with TBM cells
of STZ-DM mice (TBM-T from STZ-DM) with nonDM mice
transplanted with total bone marrow cells of nonDM mice (TBM-
T from nonDM) (Supplementary Fig. 2a). Interestingly, TBM-T
from STZ-DM donors reduced SNCV by 29% compared with
TBM-T from nonDM donors, although the blood glucose
concentrations of these two groups of mice were very similar
and well within the normal range (Supplementary Fig. 2b, c). We
found some GFP-positive cells (green), which were derived from
bone marrow, around DRG neurons in both TBM-T from
nonDM and TBM-T from STZ-DM (Supplementary Fig. 2d). In
contrast, proinsulin-positive (red) and TNF-α-positive (red) cells
were observed in DRG neurons only in those receiving TBM-T
from STZ-DM mice (Supplementary Fig. 2d middle and bottom
panels). While MAP2 expression (red) was observed in many cells
of DRG neurons in both types of mice, overlap of GFP signals
with MAP2 was seen only in donors receiving TBM-T from STZ-
DM mice (Supplementary Fig. 2d top panels). Furthermore,
proinsulin- (red) and TNF-α-positive (red) staining were also co-
localized in GFP-positive (green) cells (Supplementary Fig. 2d
middle and bottom panels). These results indicate that BMDCs
from STZ-DM mice had fused with DRG neurons and the fusion
cells expressed proinsulin and TNF-α. In other words, bone
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marrow cells that had been exposed to hyperglycemic conditions
in donor mice directly contributed to cell fusion and neuronal
dysfunction (and neuropathy) in nondiabetic recipient mice
which never exhibited hyperglycemia throughout the experiment.
TBM cells transiently exposed to diabetic conditions were capable
of inducing DN even in nonDM mice. These abnormal cells
migrated to peripheral nerves via the systemic circulation to fuse
with neurons in a recipient mouse with normoglycemia.
Since we found that LSK cells in diabetic mice included
abnormal cells expressing proinsulin and TNF-α (Supplementary
Fig. 1c, d, g, h), we next tested the potent effects of LSK cells of
































































































Fig. 1 The detection of Cell fusion in the new bone marrow transplantation model with streptozotocin-induced diabetic mice (Type 1 diabetic model). a
A schematic experimental design for a mouse model to detect cell fusion. TBM cells (4 × 106 cells) obtained from Ayu1-cre transgenic (Ayu1-cre) mice
were transplanted into 9 Gy lethally-irradiated normoglycemic Lox-stop-Lox tdTomato (lsl-tomato) mice (Ayu-1 TBM BMT to lsl-tomato). Four weeks after
BMT, Type1 diabetes mellitus was induced by intravenous STZ injection (STZ-DM) while intravenous citrate buffer injection was used as a control
(nonDM). b Blood glucose concentration of nonDM (n= 5) and STZ-DM mice (n= 4). c Relative ratio of sensory nerve conduction velocity (SNCV) in the
sciatic nerve of STZ-DM (n= 4) and nonDM (n= 5). d PCR analysis of genomic DNA from DRG neurons. While nonDM showed the presence of a 545 bp
PCR product, STZ-DM did not (Arrow). Schematic illustrating the association between the Cre-loxP system, primers, and PCR products. Blue arrowheads
showed loxP sites. (We provide the full gel image of electrophoresis as Supplementary Fig. 5.) e Histological analysis of DRG in both nonDM and STZ-DM.
Blue showed Nissl stain. Red showed tdTomato. Arrowhead indicates a tdTomato-positive DRG neuron. Scale bars= 10 μm. f Z-stack imaging of DRG from
STZ-DM. Narrow images indicate the cross-section of x-axis or y-axis (whited dotted line) in DRG neuron surrounded by white dashed line. Arrows
indicate the position of cross-section. Red showed tdTomato. Blue showed nucleus. Scale bar= 10 μm. Data are indicated as means ± SE.
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was nonDM mice with transplantation of LSK cells from STZ-
DM mice (LSK-T from STZ-DM) and the other was nonDM
mice with transplantation of LSK cells from nonDM mice (LSK-T
from nonDM) (Fig. 2a). NonDM mice with transplantation of
LSK cells from STZ-DM donors exhibited a decrease in SNCV of
36% in comparison with transplantation of LSK cells from
nonDM although blood glucose concentration was identical and
within the normal range in the two types of mice (Fig. 2b, c).
LSK-T from nonDM as well as LSK-T from STZ-DM resulted in
GFP-positive cells (green) around the DRG neurons (Fig. 2d);
however, cells with proinsulin (red) and/or TNF-α expression
(red) were present only at the DRG neurons in LSK-T from STZ-
DM mice (Fig. 2d middle and bottom panels). Immunostaining
for MAP2 (red) demonstrated that LSK-T from STZ-DM, but not
LSK-T from nonDM mice, showed yellow signals, indicating the
cell fusion of MAP2-positive neurons with GFP-positive BMDCs
(green) (Fig. 2d top panels). Furthermore, both proinsulin- (red)
and TNF-α-positive (red) reactions were simultaneously co-
localized in GFP-positive (green) cells (Fig. 2d middle and bottom
panels) so that fused cells aberrantly expressed the two factors.
Given the fact that mice with LSK-T from STZ-DM donors














































































































































































































Fig. 2 Cell fusion and development of neuropathy in mice transplanted with LSK cells from diabetic mice. a A schematic experimental design for the
transplantation of nonDM/STZ-DM LSK cells into normoglycemic mice. Diabetes (DM) was induced by STZ in GFP-Tg mice (STZ-DM GFP) while
intravenous citrate buffer injection was used for the nonDM controls (nonDM GFP). Three months later, LSK cells obtained either from nonDM or STZ-DM
mice were transplanted into 9 Gy lethally-irradiated normoglycemic wild type mice (LSK-T from nonDM or LSK-T from STZ-DM, respectively). b Blood
glucose concentration of LSK-T from nonDM (n= 8) and LSK-T from STZ-DM (n= 10). N.S means not significant. c Relative ratio of SNCV in the sciatic
nerve following LSK-T from STZ-DM mice (n= 6) compared to LSK-T from nonDM donors (n= 5). d Immunofluorescent staining of the dorsal root
ganglion (DRG) showing nuclei (blue), GFP (green), MAP2 (red), proinsulin (red), and TNF-α (red), and merged images in LSK-T from nonDM and LSK-T
from STZ-DM mice. Arrowheads showed fusion cells. Scale bars= 10 μm. e Z-stack imaging of DRG from LSK-T from STZ-DM. Narrow images indicate the
cross-section of x-axis or y-axis (whited dotted line) in DRG neuron surrounded by white dashed line. Arrows indicate the position of cross-section. Green
showed GFP. Blue showed nucleus. Scale bar= 10 μm. f FACS analysis of proinsulin-positive cells in the LSK fraction from mononuclear cells in LSK-T from
nonDM and LSK-T from STZ-DM. The percentage of proinsulin-positive cells among LSK cells (n= 3 per group). g FACS analysis of TNF-α-positive cells
among LSK cells from mononuclear cell in LSK-T from nonDM and LSK-T from STZ-DM. The percentage of TNF-α-positive cells among LSK cells (n= 5 per
group). Data are indicated as means ± SE.
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likely that diabetic neuropathy resulted from cell fusion between
the abnormal BMDCs and the local neurons (Fig. 2d, e).
Next, we examined the phenotype of LSK cells inside the bone
marrow in these mice. In mice with LSK-T from STZ-DM
donors, 2.7% and 0.6% of LSK cells were positive for proinsulin
and TNF-α expression, respectively. In contrast, both markers
were negative in LSK cells of mice following LSK-T from nonDM
donors (Fig. 2f, g).
Abnormal hematopoietic stem cells (HSCs) in the CD106
fraction. In the next set of experiments, we further characterized
LSK cells from STZ-DM mice (Fig. 3a). We found that abnormal
bone marrow cells were all positive for CD45 (Fig. 3b, c), indi-
cating that these cells belong to the hematopoietic stem cell
(HSC) population. In order to identify any factors associated with
cell fusion, the gene expression profile of LSK cells was analyzed
using microarray technology in which gene ontology (GO) using
the key term “fusion” (Supplementary Fig. 3, Gene Expression
Omnibus (GEO) accession number: GSE117088) was applied.
Using this analysis, we identified Vcam1 (CD106), Caveolin2, DC-
STAMP and Neogenin, all of which were highly expressed in the
LSK cells of STZ-DM mice compared with nonDM animals.
Interestingly, these factors have been shown to be involved in cell
fusion between progenitor cells and their maturation27–30.
Among these factors, we decided to focus on CD106 since this
molecule is a marker of activated endothelial cells and activation
of those cells is involved in the pathological process in
diabetes31,32 and vascular formation33. Previous studies also
indicate the importance of adhesion molecule in hematopoietic
stem/progenitor cells (HSPC)34,35. Fluorescent activated cell
sorting (FACS) analysis of TBM revealed that the number of
CD106-positive LSK cells from STZ-DM mice was two times
higher than that from nonDM mice (Fig. 3d). Interestingly,
CD106-positive LSK cells were also found to express TNF-α from
















































































































































































































































































Fig. 3 Localization of CD45-, CD106-, and TNF-α-positive cells in the bone marrow stem cell fraction. a A schematic experimental design for the
generation of diabetic mice (STZ-DM) and nonDM mice. b FACS analysis of LSK cell in nonDM and STZ-DM. Percentage of LSK cells in the mononuclear
cell fraction from total bone marrow in nonDM and STZ-DM. (n= 6 per group). c FACS analysis of CD45-positive cell in LSK cells from nonDM and STZ-
DM. Percentage of CD45-positive cells in the LSK cell fraction from mononuclear cells in nonDM and STZ-DM (n= 3 per group). d FACS analysis of CD106-
positive cell in LSK cells from nonDM and STZ-DM. Percentage of CD106-positive cells in the LSK cell fraction from mononuclear cells in nonDM and STZ-
DM (n= 6 per group). e FACS analysis of TNF-α-positive cells in LSK-CD106 cells from nonDM and STZ-DM. Percentage of TNF-α-positive cells in the LSK-
CD106 cell fraction from mononuclear cells in nonDM and STZ-DM (n= 6 per group). f FACS analysis of CD45-negative cell in nucleated cells in nonDM
and STZ-DM total bone marrow. Percentage of CD45-negative cells in the nucleated cell fraction in nonDM and STZ-DM total bone marrow (n= 5 per
group). g FACS analysis of TNF-α-positive cells in CD45-negative cells from nonDM and STZ-DM. Percentage of TNF-α-positive cells in the CD45-negative
cell fraction from total bone marrow in nonDM and STZ-DM (n= 3 per group). No TNF-α-positive cells were detected any mice. h Percentage of CD105-
positive cells in the CD45-negative cell fraction from total bone marrow in nonDM and STZ-DM (n= 5 per group). i Percentage of CD106-positive cells in
the CD45-negative cell fraction from total bone marrow in nonDM and STZ-DM (n= 5 per group). Data are indicated as means ± SE.
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In terms of the CD45-negative fraction (a subset of
mesenchymal stem cells), all cells were negative for TNF-α in
both STZ-DM and nonDM mice (Fig. 3f, g). Among CD45-
negative cells, the number of CD105-positive cells, which can be a
major component of the vascular niche and a precursor of
pericytes36, was significantly reduced under diabetic conditions
(Fig. 3h). In contrast, the number of CD106-positive cells in the
CD45-negative fraction was very low in both types of mice and
there was no difference in the number of CD106-positive cells
between nonDM and STZ-DM mice (Fig. 3i). Our data are
consistent with those in previous reports showing that a decrease
in CD105-positive cells in the diabetic CD45-negative fraction
was observed in blood vessels in diabetic retinopathy to account
for pericyte loss37,38.
Abnormal short-term hematopoietic stem cells appear in dia-
betes. In general, HSCs can be divided into two fractions; long-
term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs)39,40. LT-
HSCs mostly exist in the side population (SP) of LSK cells
whereas ST-HSCs exist in the remaining fraction (nonSP)41. We
first examined the population of SP and nonSP in LSK cells from
nonDM and STZ-DM. STZ-DM mice showed an increase in the
SP fraction and a decrease in the nonSP fraction compared with
nonDM mice (Fig. 4a). We further found that CD106-positive
cells were present only in the nonSP fraction in both STZ-DM
and nonDM mice; however, the percentage of CD106-positive
cells in the nonSP fraction was significantly increased under
diabetic conditions compared with nonDM conditions (Fig. 4b,
c). With respect to TNF-α expression, cells in the LSK-SP fraction
were negative in both STZ-DM and nonDM mice, while some
cells in the nonSP fraction of STZ-DM, but not nonDM mice,
were positive for TNF-α (Fig. 4d, e). Taken together, these data
show that target cells with TNF-α expression are present only in
the CD106-positive fraction of ST-HSCs in diabetic mice.
Diabetic CD106-positive HSCs can produce neuropathy in
nondiabetes. Since the number of CD106-positive cells increased
in the CD45-positive fraction of LSK cells from STZ-DM mice
(Fig. 3d), we postulated that this cell type could be the true culprit
that underlies the development of DN, and therefore designed an
experiment to address this issue. Diabetes was induced by STZ in
GFP-Tg mice, and CD106-positive and CD106-negative cells
were isolated from the LSK cell fraction of diabetic mice. Then,
the two types of cell were transplanted separately into nonDM
mice (Fig. 5a). Again, all recipient mice remained normoglycemic
throughout the entire experiment (Fig. 5b). The transplantation
of DM-CD106-positive cells decreased SNCV by 16% in nonDM
mice compared with that of DM-CD106-negative cells (Fig. 5c).
Similar to earlier experiments in this study, GFP-positive BMDCs
(green) were detected around DRG neurons of both nonDM with
DM-CD106-negative cells and nonDM with DM-CD106-positive
cells (Fig. 5d); however, the expression of either proinsulin (red)
or TNF-α (red) cells at DRG neurons was detected only in
nonDM with DM-CD106-positive cells (Fig. 5d. middle and
bottom panels). While all neurons were positive only for MAP2
in nonDM with DM-CD106-negative cells, some neurons showed
a yellow color in nonDM with DM-CD106-positive cells, sug-
gesting that GFP-positive BMDCs had merged with MAP2-
positive neurons (Fig. 5d top panels). Furthermore, either
proinsulin (red) or TNF-α (red) was also expressed in GFP cells
(Fig. 5d middle and bottom panels). Moreover GFP-positive
signal was expressed inside DRG neuron (Fig. 5e). These results
indicated that neuropathy was caused by the abnormal cells

































































































































































p = 0.019p = 0.031
Fig. 4 CD106- or TNF-α-positive cells exist in the nonSP fraction of LSK cells in STZ-DM. a FACS analysis of SP and/or nonSP fraction in the LSK cells
from nonDM and STZ-DM (left panel, SP cells surrounded by red circle, nonSP cells surrounded by orange circle). Percentage of SP fraction or nonSP
fraction in LSK cells from mononuclear cells in nonDM and STZ-DM (right panel, n= 3 per group). b FACS analysis of CD106-positive cells in LSK-nonSP
cells from nonDM and STZ-DM. Percentage of CD106-positive cells in LSK-nonSP cells from mononuclear cells in nonDM and STZ-DM (n= 3 per group).
c FACS analysis of CD106-positive cells in LSK-SP cells from nonDM and STZ-DM. Percentage of CD106-positive cells in LSK-SP cells from mononuclear
cells in nonDM and STZ-DM (n= 3 per group). No CD106-positive cells were detected in any of the mice. d FACS analysis of TNF-α-positive cells in LSK-
nonSP cells from nonDM and STZ-DM. Percentage of TNF-α-positive cells in LSK-nonSP from mononuclear cells in nonDM and STZ-DM (n= 3 per group).
e FACS analysis of TNF-α-positive cells in LSK-SP cells from nonDM and STZ-DM. Percentage of TNF-α-positive cells in LSK-SP from mononuclear cells in
nonDM and STZ-DM (n= 3 per group). No TNF-α-positive cells were detected in any mice. Data are indicated as means ± SE.
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Next, a new transplantation model was created to investigate
whether CD106 cells emerging in diabetic bone marrow would be
a new therapeutic target (Fig. 6). We isolated CD106-positive or-
negative mononuclear cells by Ficoll and FACS methods from
both nondiabetic and diabetic mice and transplanted those cells
to normoglycemic mice (Fig. 6a). As expected, the SNCV is
significantly delayed only the mice transplanted DM-CD106-
positive mononuclear cells compared with the other recipient
mice (Fig. 6b) though blood glucose concentration of all recipient
mice is within normal range (Fig. 6c). Because the mice
transplanted the CD106-negative mononuclear cells obtained
from both nondiabetic and diabetic mice were alive, we thought
that the elimination of CD106-positive fraction from the diabetic
hematopoietic stem cells is the novel strategy for the treatment of
diabetic neuropathy.
Moreover, we examined CD106 antibody treatment for
diabetic mononuclear cells to treatment diabetic neuropathy
(Fig. 7a). The SNCV of the transplanted mice after the treatment
with diabetic mononuclear cells recovered to the same level as the
transplanted mice after non-diabetic mononuclear cell treatment
and the transplanted mice after non-diabetic mononuclear cell
treatment. On the other hand, SNCV of the transplanted mice
STZ-DM GFP












































































































Fig. 5 Cell fusion and development of neuropathy in mice transplanted with LSK-CD106-positive cells from diabetic mice. a A schematic experimental
design for the generation of mouse models in this experiment. First, type 1 DM was induced in GFP-Tg mice by intravenous STZ injection (STZ-DM GFP).
Three months later, 9 Gy lethally-irradiated normoglycemic wild type mice were transplanted with LSK-CD106-positive or -negative cells obtained from
STZ-DM GFP (DM-LSK-CD106 (+ ) BMT, DM-LSK-CD106 (−) BMT, respectively). b Blood glucose concentration of DM-LSK-CD106(+ ) BMT (n= 5)
and DM-LSK-CD106 (−) BMT (n= 5). N.S means not significant. c Relative ratio of sensory nerve conduction velocity (SNCV) of the sciatic nerve in DM-
LSK-CD106 (+ ) BMT (n= 5) and DM-LSK-CD106 (−) BMT (n= 5). d Immunofluorescent staining of dorsal root ganglia (DRG) in DM-LSK-CD106 (+ )
BMT and DM-LSK-CD106 (−) BMT and for the nucleus (blue), GFP (green), MAP2 (red), proinsulin (red), and TNF-α (red), and merged images.
Arrowheads showed fusion cells. e Z-stack imaging of DRG from DM-LSK-CD106(+ ) BMT. Narrow images indicate the cross-section of x-axis or y-axis
(whited dotted line) in DRG neuron surrounded by white dashed line. Arrows indicate the position of cross-section. Green showed GFP. Blue showed
nucleus. Scale bar= 10 μm. Data are indicated as means ± SE.
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after untreated diabetic mononuclear cells was significantly
delayed (Fig. 7b). In addition, glucose concentration of recipient
mice was all within normal range (Fig. 7c).
Transient hyperglycemia induces neuropathy with cell fusion.
Our data showing that the abnormal BMDCs formed in response
to diabetic conditions are capable of evoking neuropathy despite
being under prolonged normoglycemia suggest that the insults
caused by transient diabetic conditions could be memorized in
BMDCs, and such memory could be associated with TNF-α/
proinsulin expression in CD106-positive stem cells. Among
multiple metabolic abnormalities in diabetic conditions, we
assumed that hyperglycemia could be the factor that induced the
memory effects in BMDCs. In order to address this issue, we
designed an experiment in which repeated transient hypergly-
cemic surges were induced in wild type mice with BMT from GFP
mice by repeated intraperitoneal injection of 25% glucose solution
for 14 days while saline-injected mice were used as controls







































































































































































































Fig. 6 Development of neuropathy in mice transplanted with CD106-positive mononuclear cells from diabetic mice. We isolated mononuclear cells
using ficoll-paque PLUS from nondiabetic and diabetic total bone marrow. The isolated mononuclear cells were immunoreacted by PE-conjugated anti-
CD106 antibody and sorted CD106-positive or -negative mononuclear cells by FACSAria fusion. Before anti-CD106 antibody staining, LIVE/DEAD Fixable
Dead Cell Blue stain kit was used to deplete dead cells. Sorted cells (1 ×105 cells / mouse) were transplanted into 9 Gy lethally-irradiated normoglycemic
mice. Four weeks after BMT, we measured blood glucose and sensory nerve conduction velocity. a A schematic experimental method for CD106-positive
or -negative mononuclear cells transplantation model. b Relative ratio of SNCV of sciatic nerve in nonDM CD106(−) MNCs BMT (n= 7) compared to that
in nonDM CD106(+ ) MNCs BMT (n= 5), DM CD106(−) MNCs BMT (n= 5) and DM CD106(+ ) MNCs BMT (n= 6). c Blood glucose concentration of
nonDM CD106(−) MNCs BMT (n= 7), nonDM CD106(+ ) MNCs BMT (n= 5), DM CD106(−) MNCs BMT (n= 5) and DM CD106(+ ) MNCs BMT (n
= 6). N.S means not significant. Data are indicated as means ± SE.
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significantly increased blood glucose concentration to as much as
400 mg/dL whereas saline injections remained it below 200 mg/dL
in mice (Fig. 8b). Interestingly, repeated episodic glucose injections
decreased SNCV by 14% compared with saline injection, indicating
that relatively short-term pulsative hyperglycemia for 14 days was
sufficient time for the induction of neuropathy even under non-
diabetic conditions (Fig. 8c). We next examined whether the cell
fusion process was involved in neuronal dysfunction in these mouse
models. We found the presence of bone marrow-derived GFP-
positive cells (green) at DRG sites in both (Fig. 8d); however,
proinsulin- (red) or TNF-α-expressing (red) cells were induced at
DRG neurons only in mice receiving episodic glucose injections
(Fig. 8d middle and bottom panels). Although MAP2 expression
(red) was seen in all neurons of both models, only glucose injection
induced positive signals for both MAP2 and GFP (green) in some
DRG neurons (Fig. 8d top panels). Furthermore, both proinsulin-
(red) and TNF-α (red) were induced in GFP-positive (green) cells of
mice receiving episodic glucose injections (Fig. 8d middle and bottom
panels). Furthermore GFP-positive signal was expressed inside DRG
















































































































































































































Fig. 7 Treatment of anti-CD106 antibody to diabetic mononuclear cells was improved diabetic neuropathy. We isolated mononuclear cells using ficoll-
paque PLUS from nondiabetic and diabetic total bone marrow. The isolated mononuclear cells were incubated anti-CD106 antibody (final concentration is
10 μg/ml) for 30min at 37 degree. Antibody-treated and nontreated cells (1 ×106 cells / mouse) were transplanted into 9 Gy lethally-irradiated
normoglycemic mice. Four weeks after BMT, we measured blood glucose and sensory nerve conduction velocity. a A schematic experimental method for
CD106 antibody treatment (+) or (−) mononuclear cells transplantation model. b Relative ratio of SNCV of sciatic nerve in nonDM treatment (−) MNCs
BMT (n= 5), nonDM treatment (+) MNCs BMT (n= 5), DM treatment (−) MNCs BMT (n= 5) and DM treatment (+) MNCs BMT (n= 6). c Blood
glucose concentration of nonDM treatment (−) MNCs BMT (n= 5), nonDM treatment (+) MNCs BMT (n= 5), DM treatment (−) MNCs BMT (n= 5)
and DM treatment (+) MNCs BMT (n= 6). N.S means not significant. Data are indicated as means ± SE.
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episodic glucose injections is sufficient to induce cell fusion between
BMDCs and neurons.
To clarify whether hyperglycemia itself induces the appearance
of abnormal HSCs, we examined whether repeated episodic
glucose injections could alter the phenotypes of bone marrow
cells in nonDM mice. Even though there was no change in the
percentage of LSK cells (Fig. 8f), we found that repeated episodic












































































































































































































































p = 0.016 p = 0.008 p = 0.034
Fig. 8 Cell fusion and development of diabetic neuropathy in wild mice injected intraperitoneally with 25% glucose. a A schematic experimental design
for the generation of 25% glucose- (25% Glucose) or saline- (Saline) injected wild type mice transplanted total bone marrow cells (TBM) from GFP-Tg
(GFP-TBM BMT). ip, intraperitoneal injection. b The time course of blood glucose concentrations in GFP-TBM BMT mice treated with repeated
intraperitoneal injection four times every two hour for 14 days. Arrows indicate timings of intraperitoneal injections (Saline n= 11, 25% Glucose n= 12).
Red line indicates the effect of 25% glucose injection whereas blue line shows that of saline. c Relative ratio of SNCV of sciatic nerve in Saline (n= 11)
compared to that in 25% Glucose (n= 12). d Immunofluorescent staining of dorsal root ganglion (DRG) for nucleus (blue), GFP (green), MAP2 (red),
proinsulin (red), and TNF-α (red), and merged figures. Left panel shows the effects of 25% Glucose and right panel shows that of Saline. Arrowheads
showed fusion cell. Scale bars=10 μm. e Z-stack imaging of DRG from 25% Glucose. Narrow images indicate the cross-section of x-axis or y-axis (whited
dotted line) in DRG neuron surrounded by white dashed line. Arrows indicate the position of cross-section. Green showed GFP. Blue showed nucleus. Scale
bar= 10 μm. f The effect of injection of either Saline or 25% Glucose on the percentage of LSK cells in mononuclear cell fraction from total bone marrow.
Percentage of LSK cells in the mononuclear cell fraction from total bone marrow in Saline and 25% Glucose (n= 6 per group). g Percentage of proinsulin-
positive cells in LSK cells from Saline and 25% Glucose (n= 7 per group). h Percentage of TNF-α-positive cells in LSK cell fraction from mononuclear cell in
Saline and 25% Glucose (n= 6 per group). i Percentage of CD106-positive cells in LSK cell fraction from mononuclear cell (n= 6 per group). Data are
indicated as means ± SE.
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LSK cells, but saline injections had very minor effects (Fig. 8g).
Interestingly, episodic saline injections were also found to slightly
induce proinsulin expression in LSK cells although the numbers
of such cells were extremely low. The reason might be accounted
for by mechanical stress due to repeated intraperitoneal saline
injection. With respect to TNF-α expression, positive staining was
observed in 0.5% of LSK cells, but no expression was detected in
the saline model (Fig. 8h). In turn, CD106-positive staining was
present in 7% of LSK cells in mice given saline injection but
increased to 12% of LSK in mice given glucose injections. The
difference in the number of CD106-positive cells reached
statistical significance (P= 0.034) (Fig. 8i). Next, we divided
LSK cells into two fractions (SP and nonSP), and examined the
expression of TNF-α and CD106. Glucose injections failed to alter
the population of SP and nonSP compared with saline injection
(Supplementary fig. 4a). CD106-positive cells were present only
in the nonSP fraction, but not in the SP fraction, in both models.
The percentage of CD106-positive cells in the nonSP fraction was
increased by glucose injections compared with saline injections
(Supplementary Fig. 4b, c). With respect to TNF-α expression, we
found that no cells were positive in the LSK-SP fraction of either
model while 0.2% of LSK cells in the nonSP fraction of mice given
episodic glucose injections expressed TNF-α (Supplementary
Fig. 4d, e). These results indicate that hyperglycemia could be a
mechanism for TNF-α induction in the CD106-positive fraction
of ST-HSCs. Taken together, sustained hyperglycemia over
several days appears sufficient to induce the expression of
proinsulin and TNF-α expression in ST-HSCs, transforming
those cells into the major villain that causes diabetic neuropathy.
These specific cells would therefore be a good therapeutic target
for the treatment of diabetic neuropathy.
Discussion
While DN is believed to be caused by diabetes-associated meta-
bolic abnormalities in neurons, current therapies aiming at gly-
cemic control appear inadequate as curative tools for DN. Clearly,
new hypotheses and approaches are warranted. We previously
reported that a potential mechanism for DN could be “cell
fusion” occurring between neurons and abnormal BMDCs, ori-
ginating among HSCs13,18. In this study we delved further into
the mechanisms involved and demonstrated that CD106-positive
LSK cells which emerged in bone marrow under hyperglycemia
were instrumental in inducing cell fusion in DRG neurons,
leading to neural dysfunction even in nondiabetic mice. These
results clearly indicate that DN is caused by abnormal BMDCs,
not simply by hyperglycemia-associated metabolic alterations in
nerve tissues.
DRG neurons do not physiologically express TNF-α/proinsulin
under nonDM conditions22,42. However, we demonstrated in this
study that diabetic conditions force these cells to start producing
TNF-α/proinsulin, suggesting that TNF-α/proinsulin expressions
do not mean the trans-differentiation process but indicates a
consequence of cell fusion with abnormal BMDCs. In other
words, diabetic conditions initially perturb the functions of bone
marrow cells, which then move into the systemic circulation to
reach the DRG and liver13,14. At those sites, abnormal BMDCs
fuse with resident cells to adversely affect the physiological
function of the resident cells. As such, the true culprit for the
development of DN is functionally-impaired BMDCs as these
cells express TNF-α/proinsulin in response to diabetic conditions
and cause “cell fusion” with DRG neurons. In this study, the
pathological role of diabetic bone marrow cells was also examined
in an experiment using the transplantation of bone marrow cells
from DM mice into nonDM mice under normoglycemic condi-
tion. This showed that diabetic bone marrow cells expressing
TNF-α/proinsulin cause cell fusion in nonDM mice even under
normoglycemic conditions. Among several metabolic abnormal-
ities in diabetes, hyperglycemia per se impair BMDC functions
most potently as simple glucose injection into the peritoneal
reproduced the same phenotype in BMDCs as diabetic mice.
Recently, several researchers have shown interesting findings that
diabetes could impair the mobilization of hematopoietic stem
cells and myelopoiesis as a mechanism for diabetic
complications43,44. The future study is warranted to investigate if
HSC we found could be associated with abnormal myelopoiesis.
More importantly once established, the functional impairment
of BMDCs does not return to normal even if blood glucose
control is significantly improved. This explains why these cells
can cause neuronal dysfunction in nonDM mice. It is likely that
diabetes can cause a lasting disruption of BMDC function, which
may not be immediately reversible upon restoration of normo-
glycemia. These data could account for the fact that current
therapeutic strategies aiming at glycemic control are often not
effective in treating DN in diabetic patients.
To further identify the true culprit for DN, we employed
microarray analysis and found increases in gene expression
involving multiple factors in diabetes-specific stem cells. Among
the genes affected, we focused on the CD106- (Vcam1) positive
cell population as a possible candidate because CD106 is generally
expressed in the pathological process under diabetic conditions45
and in cancer angiogenesis46. To investigate the role of CD106,
LSK-CD106-positive cells and LSK-CD106-negative cells were
transplanted separately into nonDM mice. As expected, some
TNF-α-positive cells were found only in mice receiving LSK-
CD106-positive cells but not those receiving LSK-CD106-negative
cells. The findings suggest that those CD106-positive HSCs
expressing TNF-α exhibited phenotypic change and therefore are
a candidate for diabetes-specific stem cells. Interestingly, the
pathological role of CD106-positive cells is also supported by
other studies showing that these cells are associated with chronic
inflammation and metastatic cancer47–49. Furthermore, both
integrin-alpha4 and -beta1 are expressed in DRG neurons, the
increased Vcam1 expression in diabetic LSK cells may in part play
an important role in neuronal cell fusion as indicated in Sup-
plementary fig 3. In addition, abnormal endothelial formation
may also have roles in diabetes36,50.
It is reported that CD106 does not only express on
inflammation-induced endothelial cells, but also participate in
hemopoiesis, B cell development and T cell activation51. These
reports indicate that CD106 have also important role in immu-
nological reaction. However, the model mice transplanted with
nonDM CD106(-) MNCs and STZDM CD106(-) MNCs survived
without weight loss or serious infections. These data indicate that
even in the diabetic state, LT-HSCs without CD106-positive cells
retain their stem cell integrity and have normal differentiation
potential. Thus, hyperglycemia-induced abnormal ST-HSCs are
common progenitor cells with abnormal differentiation potential
for fusion with peripheral neurons, which are specific for diabetes
and never appear in non-diabetes.
In turn, we also found that CD106-negative cells in diabetic
mice have no pathological roles in the development of DN
although those cells are also present among diabetic BMDCs. This
finding was also confirmed by an experiment in which hyper-
glycemia was induced by episodic intraperitoneal glucose injec-
tions over several days. Based on our results, eliminating
abnormal HSCs such as CD106-positive cells would be a novel
way to treat DN52.
Methods
Animal model. The Animal Care Committees of Shiga University of Medical
Science approved all experimental protocols in this study. C57BL/6 J mice (wild
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type, Japan SLC, Inc., Shizuoka, Japan), C57BL/6-Tg (UBC-GFP) 30Scha/J mice
(GFP-Tg mice, The Jackson Laboratory, Bar Harbor, ME, USA), B6.Cg-Gt(ROSA)
26Sortm9(CAG-tdTomato)Hze/J (Lsl-tdTomato mice, The Jackson Laboratory) and
Ayu1 promoter-driven Cre recombinase-expressing mice26 (Ayu1-Cre) were used.
We examined two types of diabetic mice. One was a type 1 diabetic mouse model
created by injecting streptozotocin (STZ: 150 mg/kg Body Weight) (Nacalai Tes-
que, Kyoto, Japan) into wild-type C57BL/6 J mice. The other was a type 2 diabetes
mouse model produced by feeding wild-type C57BL/6 J mice a high fat diet (HFD)
(Oriental Yeast Co., Ltd., Tokyo, Japan). The nondiabetic control group for Type 1
mice received citrate buffer (pH 4.5) injection; control mice for the type 2 model
were fed normal chow. The blood glucose concentrations of all mice were mea-
sured every week after injection of either STZ or buffer and feeding with a HFD or
normal chow. Mice were maintained under standard conditions with a 12:12-h
light-dark cycle and provided with standard laboratory chow or HFD and water ad
libitum.
First, we performed experiments using two diabetic mouse models. Type1 DM
was induced by streptozotocin (STZ) treatment (STZ-DM) (Supplementary
Fig. 1a). Type 2 DM was induced by high-fat-diet treatment (HFD-DM)
(Supplementary Fig. 1e). To monitor cell fusion, we created a new mouse model, in
which TBM from Ayu-1 Cre transgenic mice, which had a gene modification to
develop Cre recombinase from the embryonic stage26, was transplanted into LoxP-
stop-LoxP-tdTomato (lsl-tdTomato) mice, in which the tdtomato gene had been
inserted downstream of the STOP sequence inserted in the LoxP site (Ayu-1 TBM
BMT to lsl-tomato) (Fig. 1a). Type1 DM was induced by STZ-injection in
this model.
The second series of experiments was performed on a nondiabetic mouse model
that received transplantation of total bone marrow (approximately 1 ×106 cells
/mouse) obtained from diabetic mice. The bone marrow-donor mouse (GFP-Tg)
received STZ injection before bone marrow collection. Donor cells were
transplanted into nondiabetic recipient mice that had received 9 Gy radiation
before BMT (Supplementary Fig. 2a) as described previously19.
In the third series of experiments, we used nondiabetic recipient mice that had
received LSK fraction hematopoietic stem cells (HSCs) collected from diabetic mice
(Fig. 2a). Mononuclear cells were isolated from total bone marrow cells using
Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), and stained
with LIVE/DEAD Fixable Blue Dead cell stain kit (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) to selectively deplete dead cells. The isolated mononuclear
cells were washed with phosphate buffered saline (-) (PBS (-)), suspended in Flow
Cytometry Staining Buffer (eBiosciences, Inc., San Diego, CA, USA), and stained
with a Biotin Mouse Lineage Panel that includes the following antibodies: anti-
CD3e, anti-CD11b, anti-CD45R, anti-Gr-1, and anti-TER119 (BD Biosciences, San
Jose, CA, USA), followed by fluorescent antibodies: Phycoerythrin (PE)-Cy7-
conjugated streptavidin, allophycocyanin (APC)-conjugated anti-c-kit, and APC-
Cy7-conjugated anti-Ly6A/E (Sca-1) (all antibodies were purchased from BD
Biosciences). Finally, LSK cells were sorted on a FACS Aria Fusion (BD
Biosciences). The isotype-matched control antibodies were used to define the gate
threshold of specific antibodies. The lineage-negative gate was obtained by the
addition of PE-Cy7 streptavidin-conjugated antibody. Approximately 1 × 103 LSK
cells were then transplanted into lethally-irradiated wild-type mice (called LSK-T
from nonDM or LSK-T from STZ-DM, respectively). Weekly measurement of
blood glucose concentration at 9:00 AM was started at 4 weeks. After LSK cells
were sorted according to the expression of CD106 in diabetic mice, either LSK-
CD106-positive cells or LSK-CD106-negative cells were transplanted into
nondiabetic mice to create two types of mouse models; DM-LSK-CD106 (+ ) BMT
or DM-LSK-CD106 (-) BMT, respectively (Fig. 5a).
Finally, we performed experiments using nondiabetic mice with glucose-
injection induced hyperglycemia. The nondiabetic mice received BMT
(approximately 1 ×106 total bone marrow cells/100ul /mouse) from nondiabetic
GFP-Tg mice and received intraperitoneal injections of 25% glucose solution (3 g/
kg Body Weight) or saline four times a day for 14 days (Fig. 6a). Blood glucose
concentration was measured at 4 time-points (0, 15, 30 and 120 minutes) after each
injection.
To examine whether the diabetic CD106-positive cells are novel therapeutic
target, we made two transplantation models, first: the normoglycemic mice that
received the transplantation of CD106-positive or -negative mononuclear cells
obtained from nondiabetic and diabetic bone marrow (Fig. 7), second: the
normoglycemic mice that received the transplantation of mononuclear cells
obtained from nondiabetic and diabetic bone marrow with or without anti-CD106
antibody treatment (Fig. 8). Anti-CD106 antibody (biolegend Inc., Clone 429
(MVCAM.A), final concentration:10 μg/ml) was utilized in order to neutralize the
adhesive action of CD106 mononuclear cells at DRG neurons.
Determination of blood chimerism after BMT. To examine the re-establishment
of the hematopoietic system, peripheral blood was taken from the saphenous vein,
and analyzed by FACS to determine the proportion of GFP-positive cells in per-
ipheral blood at 12 weeks after transplantation of total bone marrow, LSK cells, or
LSK-CD106-positive cells using a FACS Canto II and FACS DIVA software (BD
Biosciences). We selected only mice with more than 90% of peripheral white blood
cells of donor origin for further study.
Sensory nerve conduction velocity. In order to expose the sciatic nerve, the skin
was cut at the left dorsal surface of the thigh to measure sensory nerve action
potential (SNAP) using a Medelec Sapphire electromyograph (Medelec, Woking,
UK) under anesthesia at 30 to 32 °C (13, 18), and sensory nerve conduction
velocity (SNCV) was calculated.
Immunofluorescent staining of the dorsal root ganglion. After exsanguination,
mice were perfused with fixative to collect a dorsal root ganglion (DRG) as pre-
viously described13,18. Eight μm-thick frozen sections were immunostained with
the following antibodies: rabbit anti-MAP2, rabbit anti-insulin (Cell signaling
technologies, Danvers, MA USA) or rabbit anti-TNF-α (Abcam plc. Cambridge,
UK) as primary antibodies, followed by Alexa555 anti-rabbit IgG antibody as the
secondary antibody (Thermo Fisher Scientific). Finally, sections were mounted
with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame,
CA, USA), and then analyzed by confocal laser-scanning microscopy (CLS, EZ-C1
software, Nikon, Tokyo, Japan). TdTomato-fluorescence expression was detected
by histological analysis. NeuroTrace Fluorescent Nissl stain (Thermo Fisher Sci-
entific) was used for the detection of DRG neurons.
Expression of TNF-α, proinsulin, and CD106 by LSK cells. To evaluate TNF-α
and CD106 expression, we isolated mononuclear cells from total bone marrow
using Ficoll-Paque Plus with PE-Cy7-conjugated streptavidin antibody, followed by
immunoreaction with APC-conjugated anti-c-kit, APC-Cy7-conjugated anti-Ly6A/
E (Sca-1), fluorescein isothiocyanate (FITC) -conjugated anti-CD106 or FITC-
conjugated anti-CD45 and phycoerythrin (PE)-conjugated anti-TNF-α (eBios-
ciences) after Biotin Mouse Lineage Panel staining. To evaluate proinsulin
expression, mononuclear cells were fixed with BD Cytofix/CytoPerm (BD Bios-
ciences) after reacting with PE-Cy7-conjugated streptavidin antibody, APC-
conjugated anti-c-kit, APC-Cy7-conjugated anti-Ly6A/E (Sca-1), and Biotin Mouse
Lineage Panel. Then a rabbit anti-insulin monoclonal antibody (Cell signaling
technology) and PE-conjugated anti-rabbit IgG antibody (Cell signaling technol-
ogy) were applied to mononuclear cells. To deplete dead cells, LIVE/DEAD Fixable
Dead Cell Blue stain kit was used before staining. Four hours after staining, cells
were analyzed using a FACS Canto II with FACS DIVA software (BD Biosciences).
Genomic DNA analysis. In order to confirm deletion of the stop sequence in DRG
neurons as a consequence of cell fusion, genomic DNA was extracted from DRG
neurons in either diabetic or nondiabetic condition of Ayu-1 Cre TBM lsl-tomato
mice by NucleoSpin DNA FFPE XS kit (MACHEREY-NAGEL GmbH & Co. KG,
Düren, Germany), and PCR was performed by TaKaRa Ex Taq (TaKaRa BIO INC.,
Kusatsu, Shiga, japan). Following primers were used: Forward: 5′-GCTGATC
CGGAACCCTTAA-3′ and Reverse: 5′-CCCATGGTCTTCTTCTGCAT-3′.
Microarray analysis. RNA was isolated from LSK cells using a RNeasy Plus Micro
kit (Qiagen, Tokyo, Japan). The RNA samples were analyzed by TaKaRa bio (Shiga,
Japan) using a Nanodrop and Agilent 2100 BioAnalyser. The RNA samples were
amplified by the Ovation Pico WTA system, and used to perform microarray
analysis.
Mesenchymal stem cell analysis. We performed FACS analysis to characterize
the bone marrow mesenchymal stem cells obtained from diabetic and nondiabetic
mice. For the preparation of nucleated cells, total bone marrow cells were collected
and hemolyzed in ammonium chloride-based red blood cell lysis buffer for 60 s,
then washed twice with PBS(-). Nucleated cells were stained with PE-Cy7-
conjugated anti-CD45 antibody (BioLegend Inc., San Diego, CA, USA), APC-Cy7-
conjugated anti-Ly6A/E (Sca1), APC-conjugated anti-CD105 (BioLegend Inc.), or
FITC-conjugated anti-CD106. Before specific antibody staining, LIVE/DEAD
Fixable Dead Cell Blue stain kit was used to deplete dead cells. Finally, a FACS
Canto II with FACS DIVA software (BD Biosciences) was used for data collection
and analysis.
Analysis of the side population in LSK cells. The side population (SP) of LSK
cells was analyzed by FACS according to the method reported by Goodell53. Total
bone marrow cells were stained with Hoechst33342 dye (Sigma-Aldrich Japan K.K.,
Tokyo, Japan) for exactly 90 min at 37 °C. Hoechest33342-positive cells were
incubated with verapamil hydrochloride (Tocris bioscience, Bristol, UK) for gate
setting, and then mononuclear cells were separated by Ficoll-Paque Plus. Next,
these cells were incubated with PE-Cy7-conjugated streptavidin, APC-conjugated
anti-c-kit, APC-Cy7-conjugated anti-Ly6A/E (Sca-1) and PE-conjugated anti-TNF-
α or FITC-conjugated anti-CD106 after Biotin Mouse Lineage Panel staining.
Finally, for dead cell depletion, propidium iodide (Sigma-Aldrich) was added to the
samples to remove dead cells before analysis using a FACS Aria Fusion with FACS
DIVA software (BD Biosciences).
Statistical analysis. In this study, we performed unpaired student’s t-test to
evaluate between 2 groups or ANOVA among 4 groups. All data are showed as
means ± SE and P < 0.05 indicated significantly differences.
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Statistics and Reproducibility. For statistical analysis of the results, t-test was
performed between the two groups, and one-way ANOVA Tukey’s post hoc
analysis was performed between the four groups. The t-test was performed using
Microsoft Excel, and one-way ANOVA was performed using SPSS software version
22 (IBM, Armonk, New York, USA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All raw data that were graphed are provided as Supplementary data. The microarray
results of this study have been deposited in the Gene Expression Omnibus (GEO) with
Accession number is GSE117088. All other data are available from the corresponding
author on reasonable request.
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